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Development and Validation of Clinical Whole-Exome
and Whole-Genome Sequencing for Detection of
Germline Variants in Inherited Disease
Madhuri Hegde, PhD; Avni Santani, PhD; Rong Mao, MD; Andrea Ferreira-Gonzalez, PhD;
Karen E. Weck, MD; Karl V. Voelkerding, MD

 Context.—With the decrease in the cost of sequencing,
the clinical testing paradigm has shifted from single gene to
gene panel and now whole-exome and whole-genome
sequencing. Clinical laboratories are rapidly implementing
next-generation sequencing–based whole-exome and
whole-genome sequencing. Because a large number of
targets are covered by whole-exome and whole-genome
sequencing, it is critical that a laboratory perform
appropriate validation studies, develop a quality assurance
and quality control program, and participate in proficiency
testing.
Objective.—To provide recommendations for wholeexome and whole-genome sequencing assay design,
validation, and implementation for the detection of germline variants associated in inherited disorders.
Data Sources.—An example of trio sequencing, filtration

and annotation of variants, and phenotypic consideration
to arrive at clinical diagnosis is discussed.
Conclusions.—It is critical that clinical laboratories
planning to implement whole-exome and whole-genome
sequencing design and validate the assay to specifications
and ensure adequate performance prior to implementation. Test design specifications, including variant filtering
and annotation, phenotypic consideration, guidance on
consenting options, and reporting of incidental findings,
are provided. These are important steps a laboratory must
take to validate and implement whole-exome and wholegenome sequencing in a clinical setting for germline
variants in inherited disorders.
(Arch Pathol Lab Med. 2017;141:798–805; doi: 10.5858/
arpa.2016-0622-RA)

T

clinical test by several laboratories.3 The primary clinical
application of WES and WGS is in the setting of the
undiagnosed patient with a suspected genetic disorder,
where other testing modalities have been inconclusive or
noninformative.4,5 Secondarily, WES is being used by some
laboratories as a broad-scale approach to gene enrichment
and sequencing followed by bioinformatically targeted panel
analysis for specific disorders (eg, hypertrophic cardiomyopathy). We discuss the technical validation of WES and
WGS with respect to assay design, validation, performance
characterization, and implementation in a clinical laboratory. The critical aspect of bioinformatics analysis and use of
databases in analysis and clinical interpretation is also
discussed.

he onset of next-generation sequencing (NGS) technology has resulted in a vast increase in genetic diagnostic
testing available to the ordering physician. Whole-exome
sequencing (WES) has become available as a diagnostic test
performed in Clinical Laboratory Improvement Amendments–certified and College of American Pathologists–
accredited clinical laboratories.1,2 In addition, whole-genome sequencing (WGS) is starting to be implemented as a
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WES AND WGS AS A NEW GENETIC DIAGNOSTIC
PARADIGM
Use of WES or WGS as a diagnostic test has changed the
testing strategy from focusing on sequencing only those
genes known to cause a particular disorder or phenotype to
sequencing all genes in the genome and focusing the
analysis on those genes that may directly explain the
individual’s phenotype (eg, congenital hearing loss, epilepsy).6 Although this initial analytical approach is conceptually
similar to a multi-gene panel, WES and WGS offer the
advantage of expanding the search space to consider
additional genes that may potentially explain an individual’s
complex or peculiar clinical presentation (Figures 1 and 2).
Whole-Exome and Whole-Genome Sequencing—Hegde et al

Figure 1. Exome sequencing bioinformatic analysis in a clinical laboratory for variant filtration. Abbreviations: ACMG, American College of Medical
Genetics; EVS, Exome Variant Server; VCF, variant call file; VUS, variant of uncertain significance.

Figure 2. Annotation variants using Human
Phenotype Ontology (HPO) terminology for
phenotype prioritization. Abbreviations: IBD,
identity by descent; WES, whole-exome sequencing; WGS, whole-genome sequencing.
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From an analytical diagnostic perspective, WES and WGS
pose a unique data reduction exercise. A single exome
generates approximately 30 000 variants and a genome
generates more than 3 million variants that differ from the
human reference genome. The diagnostic task is to
bioinformatically filter, curate, and interpret a small fraction
of these variants in the context of the patient phenotype.
Through WES/WGS, one may uncover novel variants not
known to be associated with disease, variants causing
extremely rare diseases that were not considered in the
differential diagnosis, or rare variants in specific populations, that are not deemed as disease causing.7,8 Much of the
challenge today is the analysis and classification of genomic
variants that have not been previously reported in the
medical literature or in public databases for different
populations.9 The assessment of pathogenicity of variants
follows accepted guidelines for variant classification, but
when insufficient evidence is available to determine the
benign or pathogenic nature of a given variant, it remains as
a variant of uncertain significance.10
The application of WES in the setting of undiagnosed
patients with suspected genetic etiologies has been shown
to yield a diagnostic rate of approximately 28% to 32% in
larger patient series.11–13 As discussed further below, WES/
WGS may also identify pathogenic variants in genes
associated with disorders other than the phenotype under
investigation. These so-termed incidental or secondary
findings may reveal carrier status for recessive disorders,
genetic predisposition to cancer, and other treatable or
nontreatable diseases with reduced penetrance and variable
expressivity and age of onset.
Though technical advances are continuing to occur in
WES/WGS, they are not all-in-one comprehensive tests.
Because of sequencing and bioinformatics limitations, a
significant number of clinical conditions cannot be tested for
using WES/WGS and require alternate diagnostic technical
approaches. These include, but are not limited to, nucleotide
repeat expansion disorders and methylation disorders.
Examples of these disorders include trinucleotide repeat
disorders such as Huntington disease, myotonic dystrophy,
fragile X syndrome and spinocerebellar ataxias, Duchenne/
Becker muscular dystrophy: exon duplications in the DMD
gene; Charcot-Marie-Tooth disease type 1A and hereditary
neural pressure palsy: 1.3-Mb duplication at 17p12 (reciprocal deletion for hereditary neural pressure palsy); myotonic dystrophy types 1 and 2: CTG trinucleotide repeat
(type 1) and CCTG tetranucleotide repeat (type 2);
facioscapulohumeral muscular dystrophy, type 1: contraction of D4Z4 repeat at 4q with permissive 4qA telomeric
haplotype; and spinal muscular atrophy (95%): homozygous
deletion of SMN1. Methylation defects in disorders such as
Beckwith-Wiedemann, Prader-Willi, and Angelman syndromes also cannot currently be detected using WES/WGS.
WES AND WGS—ASSAY DESIGN
For WES to be considered a stand-alone, first-tier test,
there is a need to achieve as complete coverage as
technically possible of all exons of known genes associated
with disease. Complete coverage across all exons, however,
is a challenge because certain regions in the genome are
difficult to sequence and/or bioinformatically analyze,
including GC-rich regions, repeat expansions, and regions
of high sequence homology (eg, pseudogenes). Difficulty is
further encountered in sequencing, detecting, and analyzing
800 Arch Pathol Lab Med—Vol 141, June 2017

large insertions and deletions (indels), copy number
variants, and other structural variants. Greater success has
been achieved in detecting these types of variants when
using WGS because of the greater contiguous coverage of
the genome.
The technical workflow for WES typically involves an
initial preparation of an NGS overlapping fragment library
from genomic DNA. The fragment library is then hybridized
in solution with oligonucleotide capture probes, and the
captured fragments are further purified and, in some
protocols, amplified by limited cycles of polymerase chain
reaction. The resulting enriched library is quantified and
subjected to sequencing. Capture probe content varies
among commercial reagent sets but focuses on coding
regions (exons) and their proximal intronic flanking
sequence, and may also include as targets 5 0 and 3 0
untranslated region sequences. Of the Clinical Laboratory
Improvement Amendments–certified laboratories listed in
GeneTestingRegistry.org (accessed January 10, 2017) that
provide exome sequencing diagnostic testing, the most
commonly used capture approach involves hybridization
with Agilent SureSelect probe technology (Agilent Technologies, Santa Clara, California), followed by Roche
Nimblegen Inc (Madison, Wisconsin) and Illumina Inc
(San Diego, California), though versions and products vary
among different laboratories.
Of the approximately 22 000 genes in the human genome,
approximately 5200 genes are known to be associated with
disease (Online Mendelian Inheritance in Man).41 This
number is dynamic because new gene-disease associations
are discovered on a regular basis. In designing WES, one
strategy is to use an enrichment approach that provides as
complete coverage as technically feasible for the coding
regions and flanking intron-exon boundaries (eg, 10–50
base pairs ) of genes with known disease associations. This
approach may require the addition, or ‘‘spiking in,’’ of
probes to an existing exome enrichment reagent, resulting
in a hybrid of broader coding-region coverage complemented by increased coverage in disease-associated genes.
Characterization of capture efficiency and coverage typically
requires bioinformatics algorithms that can scan aligned
sequence reads and generate coverage statistics. It is
optimum to include in the capture enrichment any genespecific deep intronic and untranslated regions associated
with diseases. This requires a continuous curation of the
literature and subsequent enhancements to exome-capture
libraries. Sanger sequencing of low-coverage regions may
be indicated for select genomic regions likely to be
associated with the patient’s clinical phenotype. Additional
targets covered by exome sequencing may include ancestry
markers, which may in turn explain the detection of founder
pathogenic variants, pharmacogenetic loci, and genomewide association markers.14
In contrast to WES, WGS does not require capture-probe
enrichment. In a relatively simpler workflow, an NGS
fragment library is prepared from genomic DNA, quantified,
and subjected to sequencing. Not performing capture probe
enrichment, as required for WES, results in less-biased
sequence coverage. For example, GC-rich regions such as
those often found in the first exon of genes show reduced
coverage relative to other exons in WES. This bias is less
prominent in WGS. The more contiguous nature of WGS
allows inspection of deeper intronic and regulatory regions
as well as the application of WGS-specific bioinformatics
algorithms for the detection of structural variation.15,16 These
Whole-Exome and Whole-Genome Sequencing—Hegde et al

additional features can be particularly advantageous when
investigating a recessive condition in which 1 of the 2
pathogenic variants resides in a coding region and the other
variant resides deeper in an intron (eg, a deep intronic
variant that impacts splicing) or may be an exonic deletion.
Although there are technical advantages to WGS compared with WES, current barriers to its broader clinical use
include a substantial increase in sequencing cost to generate
adequate coverage of the entire genome compared with
WES. Further, analysis of WGS requires a substantial
increase in computational resources. As these barriers
decline it is anticipated that a progressive conversion from
WES to WGS will occur in clinical diagnostics. Several NGS
platforms are available that have sufficient sequencing
throughput for WES and WGS, for example, the HiSeq
series from Illumina and Proton platform from the ThermoFisher Scientific (Waltham, Massachusetts) subsidiary Ion
Torrent.17
BIOINFORMATICS FOR WES AND WGS
Whole-exome sequencing and WGS generate large data
files whose analysis requires substantial computational
infrastructure and expertise. A variety of open-source
algorithms and commercial software exist that are capable
of processing WES and WGS data files. The diversity of
available tools is reflected in clinical practice by the fact that
each diagnostic laboratory performing WES and WGS has a
unique analytical pipeline. These pipelines are often a
compilation of open-source, in-house–developed, and
commercial software.
Although variations on the protocol exist, there are shared
basic bioinformatics processes involved in the analysis of
WES and WGS data. The multistep analysis of WES and
WGS includes the processes of initial alignment and mapping
of sequence reads to the human genome reference in order to
generate a binary alignment and mapping file (primary
analysis), followed by generation of a variant call file with
associated annotations (secondary analysis) in preparation for
downstream clinical interpretation, which is dependent upon
variant prioritization, classification, and integration with the
patient phenotype (tertiary analysis). A substantial technical
literature exists focusing on the primary and secondary
analyses of WES and WGS data. Of paramount interest has
been the characterization of different algorithms for alignment and variant calling, with an emphasis on characterizing
their relative completeness and accuracy for determining
sequence variation. As this topic is beyond the scope of the
current manuscript, the reader is referred to several reviews
for greater detail.18–20 The tertiary analysis of WES and WGS
is complex and requires overlapping yet unique data-mining
strategies compared with the interpretation of NGS targeted
gene panels for specific disorders. Herein we will focus on
strategies that are used when evaluating an undiagnosed
patient with a suspected genetic etiology and provide an
example.
An overarching consideration when applying WES/WGS
is the choice of sequencing only the presenting patient
(proband) versus the proband and biological parents (trio)
when they are available. Studies have demonstrated that trio
sequencing provides a higher diagnostic yield, as it allows
for a more detailed analysis of variant inheritance patterns.
Whether applied to probands or trios, the analysis of WES/
WGS data for identifying the genetic etiology of an
undiagnosed disorder is guided by the hypothesis that the
Arch Pathol Lab Med—Vol 141, June 2017

causative variant(s) is rare in the population and that it is
penetrant.11 Based on this premise, several analytical
approaches can be taken. One manual approach is to
generate a list of genes that have been associated with the
patient phenotype using medically curated databases (eg,
the Human Gene Mutation Database) and disease-specific
databases (eg, Leiden Open Variation Database), and crosscheck the annotated variants for any known pathogenic
variants that reside within the gene list. Although this
approach may yield a genetic21 diagnosis, it is operationally
difficult to apply in a laboratory setting where multiple
examples with a diversity of complex phenotypes are being
analyzed.9,22 To achieve efficiency of analysis, most laboratories establish a workflow comprising a series of steps that
progressively filter and prioritize variants for cross-correlation with phenotype. To the degree possible, laboratories
are leveraging either in-house–developed or commercially
available software to achieve this aim.
An example of an exome analysis workflow is shown in
Figure 1. A common starting point is to exclude by filtration
variants that are common in the population. The choice of
population frequency to be applied as a filter may differ
among laboratories and individual patients. As an example,
it is common to filter out variants that are present at an
allele frequency equal to or greater than 1% in the
population. A systematic analysis using stratified European
and African American populations in the Exome Variant
Server and the Broad Institute Exome Aggregation Consortium and Genome Aggregation Database23 (www.ExAC.org;
http://gnomad.broadinstitute.org, both accessed January 10,
2017) can be used for determining minor allele frequency
estimations. Recently, the beta version of the Genome
Aggregation Database was made available by this consortium. This data set contains 126 216 exomes and 15 137
genomes from unrelated individuals in disease-associated or
population studies. With the remaining variants, further
prioritization is based on additional features, including the
functional impact of the variant. Protein-altering variants,
including truncating variants (stop gain/loss, start loss, or
frameshift), missense variants, canonical splice-site variants,
and variants within the intron-exon boundary predicted to
alter splicing may initially be considered, followed by other
types of variants such as silent and in-frame indels affecting
protein-coding regions. Missense variants can be further
characterized by using in silico functional impact prediction
tools such as Sorting Intolerant From Tolerant (http://sift.
jcvi.org/, accessed January 10, 2017) and Polyphen (Polymorphism Phenotyping V2; http://genetics.bwh.harvard.
edu/pph2/, accessed January 10, 2017), among others.24
This set of annotated variants can be further stratified into
those that are present in the same gene, those that are
predicted to be the most deleterious, and ultimately those
that reside in genes that have been associated with the
patient phenotype. In proband sequencing, subsequent
variant analysis and phenotype correlation focus on the
individual, whereas with trio WES variants can importantly
be analyzed for mode of inheritance, to determine variant
phasing (ie, cis versus trans) with respect to parental
genotype and whether a given variant is de novo.
Diagnostic matching of prioritized variants with patient
phenotypes requires considerable expertise coupled with a
strategy for correlating signs and symptoms with the
reported literature. This represents a substantial time
commitment in the analysis of WES and WGS data. Key
phenotypic terms from the patient’s clinical indication and,
Whole-Exome and Whole-Genome Sequencing—Hegde et al 801

when available, segregation information and family history,
can be used to triage and prioritize variants for pathogenicity assessment (Figure 2). A careful review of the patient’s
phenotype is therefore critical prior to data analysis. External
laboratories may request patient charts and internal
hospital-based laboratories may have access to the patient’s
electronic medical records. As part of an extensive chart
review, including clinical history and key phenotype terms, a
clinical geneticist, a laboratory director, and/or a genetic
counselor can review previous laboratory results, patient
photographs, and family history. Once phenotypic features
are obtained, cross-correlation with a set of prioritized
variants is undertaken. This process is approached either
manually or with the aid of variant-prioritizing software that
incorporates phenotypic terms. To standardize phenotype
terms, the Human Phenotype Ontology (HPO) can be
used.25,26 Although the HPO database is extensive, it is
important to be aware of its limitations. For example, at
present, all phenotype terms may not be captured using
standardized HPO terminology, thereby affecting the
sensitivity of the informatics tools that use HPO terms for
variant prioritization. Using standardized HPO terms and
variant information, algorithms such as Exomizer and
others27–30 can be leveraged to prioritize variants based on
phenotype, genotype, and predicted impact on protein
function. Each variant has to meet specific quality control
thresholds determined by the laboratory. In terms of
functional annotation, protein-altering variants, including
truncating variants (stop gain/loss, start loss, or frameshift),
missense variants, canonical splice-site variants, and variants within the intron-exon boundary (flanking the exonic
boundaries) predicted to affect splicing are prioritized,
followed by other types of variants such as silent and inframe indels affecting protein-coding regions. A systematic
analysis of the stratified European and African Americans in
the Exome Variant Server and Broad Institute Exome
Aggregation Consortium databases can be used for determining minor allele frequency estimations to establish (1)
germline de novo mutations, also absent in the available
control populations (extended to include mitochondrial
DNA sequence by requiring mother to have only the
reference allele while the patient has only the mutant allele);
(2) recessive homozygous genotypes, which are heterozygous in both parents, never homozygous in controls, with a
control allele frequency of less than 0.5%; (3) hemizygous X
chromosome variants inherited from an unaffected heterozygous mother, with a control allele frequency of less than
1% and never observed in male controls or homozygous in
female controls; and (4) compound heterozygous genotypes
in the patient (1 variant inherited from each heterozygous
parent, with the 2 variants occurring at different genomic
positions within the same gene), for which neither variant is
ever homozygous in controls, and each has a control allele
frequency of less than 1%. For the compound heterozygous
genotypes, trio analysis facilitates variant phasing.
The laboratory may communicate with the referring
physician and genetic counselor to discuss the results and
the potential of the findings to explain the clinical
presentation of the patient. This communication offers the
opportunity for collaborative input into the provisional
diagnostic result, which sometimes can result in additional
analyses that factor into the final diagnostic report. Finally,
given the rapid pace of discovery of new gene-disease
associations, periodic reanalysis of WES/WGS data may
802 Arch Pathol Lab Med—Vol 141, June 2017

result in establishment of a diagnosis not previously
achievable.
WES AND WGS INCIDENTAL FINDINGS
Incidental or secondary findings present a challenge to
medical professionals who work with WES and WGS. An
incidental finding is often described as an additional finding
unrelated to the original indication for a particular evaluation. In 2013, an American College of Medical Genetics and
Genomics (ACMG) working group published a recommendation that laboratories performing exome or genome
sequencing routinely analyze and report pathogenic or
expected pathogenic variants from a set of 56 genes
associated with an aggregate total of 24 disorders.31 The
disorders are primarily cancer-predisposition syndromes and
inherited cardiovascular disorders such as hypertrophic
cardiomyopathy. These are referred to as incidental or
secondary findings; the rationale for their inclusion is that
they represent medically actionable findings. The original list
of 56 genes was recently updated to 59.32 The original
publication by the ACMG was met with opposition from
professionals who argued that routine examination of exome
or genome for secondary findings did not respect patient
autonomy. In response, the ACMG issued a policy statement
that acknowledged the importance of patient autonomy and
recommended that informed consent for exome or genome
sequencing be accompanied by the option to include analysis
for incidental findings. Going forward, the topic of secondary
findings will continue to be discussed, with additional areas
suggested for inclusion being genes associated with autosomal recessive disorders and pharmacogenetic variants that
influence metabolism of more commonly prescribed medications. If a laboratory performing exome or genome
sequencing reports secondary findings, then its assay must
be validated for the corresponding genes in terms of
adequate sequence read coverage and ability to accurately
identify variants. The performance of reportable incidental
findings should generally be as reliable as the reporting of
the primary test results. Laboratories may choose to develop
policies on incidental findings, including the type of variant
that would be reported (eg, pathogenic, expected pathogenic, and/or likely pathogenic). It is important for the laboratory
to disclose its policies on reportable variants for incidental
findings and describe the test limitations.
CONFIRMATION OF NGS FINDINGS
When exome and genome sequencing were initially
introduced for clinical diagnostic purposes, it was routine
to Sanger sequence NGS findings prior to reporting. With
advances in chemistries and bioinformatics analyses, the
accuracy of NGS has substantially improved. This has
allowed clinical laboratories to empirically determine quality
thresholds for variant identification that do not require
Sanger confirmation.33 The value of reducing the extent of
Sanger confirmation is improved turnaround time for
reporting and reduced costs. Each laboratory must establish
performance metrics and quality thresholds to determine
the need for Sanger confirmation for their exome or genome
sequencing protocol. For example, a laboratory may
determine that a substantial proportion of Sanger sequencing can be eliminated for single- nucleotide variants
(meeting preset quality thresholds), whereas Sanger confirmation for insertions and deletions is warranted. Other
variant types, especially copy number and other structural
Whole-Exome and Whole-Genome Sequencing—Hegde et al

variations, which are identified by exome or genome
sequencing, may require confirmation by orthogonal
methods. Examples would include larger deletions confirmed by a comparative genomic hybridization microarray.
PROGRAMMATIC CONSIDERATIONS FOR WES AND
WGS—PROBAND AND TRIO SEQUENCING
Clinical laboratories may offer sequencing of the proband
only and/or trio sequencing (analysis of the proband and
parents) by WES or WGS. The advantages of performing
trio sequencing are that it significantly helps in determining
the segregation of variants (cis or trans) for autosomal
recessive disorders, and in determining the inheritance
nature of the variant (de novo or inherited) for autosomal
dominant disorders. Trio sequencing can thus aid with the
interpretation of the clinical significance of a sequence
variant identified in the proband and has been shown to
result in an increased diagnostic rate. During test design and
validation, laboratories should validate the assay and the
bioinformatics pipelines to investigate data from proband
alone and/or trio analysis, if relevant. Analysis of proband
alone typically yields a greater number of variants of
uncertain significance for further investigation because
inheritance is not known. For proband-alone testing,
additional assays such as targeted single-nucleotide polymorphism array testing may need to be performed to
confirm identity, whereas analysis of trios provides confirmation of identity and parentage. Cross-specimen contamination may be detected using laboratory-developed
protocols or previously described methods implemented.34
CONSENT OPTIONS IN WES AND WGS
Laboratories should create a policy around requirements
for consent to be provided along with the request for WES
testing for a proband and/or trio. The consent form may
provide information about the types of diagnostic results
that will be reported versus opt-in requesting for different
types of genomic results. For example, consent for results
may include (1) diagnostic findings related to the clinical
phenotype and (2) diagnostic findings not related to
phenotype for childhood-onset disorders. Analysis of trios
raises a number of consent options, which need to be
addressed for both the proband and the parents and for
additional family members tested in the program, including
discovery of falsely assigned paternity. A laboratory should
determine reporting policies during the validation of the
assay before offering WES or WGS clinically.
Other optional disclosures may include carrier status for
autosomal recessive conditions; pharmacogenetic variants;
diagnostic findings not related to phenotype for adult-onset,
medically actionable disorders; and diagnostic findings not
related to phenotype for adult-onset, medically nonactionable findings (eg, for patients 18 years or older). These
options should be considered for the proband and
additional family members separately. Both ACMG and
the Association of Molecular Pathology have published
guidelines for reporting additional incidental findings.32,35
EXAMPLE
A proband with profound developmental delay, dysmorphic facial features, hypotonia, osteopenia, seizure disorder,
microcephaly, seizures, and poor muscle mass was referred
for WES. Brain imaging showed an abnormality of
diencephalon. A total of 29 860 variants were detected
Arch Pathol Lab Med—Vol 141, June 2017

from trio exome sequencing. A total of 19 160 genes were
covered in the WES assay. The pseudogenes were removed
from the variant parsing as shown in Figure 2. A total of
212 786 exons were covered and 2066 exons had less than
203 coverage (~1%). A total of 29 860 variants were
detected, and, based on the phenotype, 11 variants were
selected for further follow-up. These variants, along with a
variant in the ASXL3 c.3349C.T (p.R1117X), were considered genes of interest after prioritization by filtering and
phenotype correlation, as shown in Figure 3, A (NGS reads)
and B (pedigree and Sanger confirmation). The ASXL3 gene
is a recently reported gene associated with disease.
Pathogenic variants in the ASXL3 gene cause BainbridgeRopers syndrome. To date, a total of 6 examples have been
reported, inherited in autosomal-dominant fashion and
were de novo. The phenotypic features overlap with those
of Bohring-Opitz syndrome.36 Discussion with the physician regarding phenotype and additional familial testing led
to the variant being classified as pathogenic. Targeted
testing in the parents did not detect the c.3349C.T
(p.R1117X) variant in either parent. The c.3349C.T
(p.R1117X) variant was classified as likely pathogenic
(Figure 3).37
ASSAY VALIDATION
Most guidelines published by ACMG and other organizations state that WES should be performed at an average
read coverage depth of 1003 and a minimum depth of 203
for variant assessment.38–40 Whole-genome sequencing is
generally performed at a depth of 303, but no specific
guidelines for WGS in clinical sequencing are available.
Because of the large amount of genomic information that
exome and genome sequencing interrogate, the most
practical approach to assay validation is to perform a
methods-based validation and include samples that contain
a spectrum of variants (eg, single-nucleotide variations and
indels) that the assay is intended to detect. This can be
supplemented by samples with known pathogenic variants
(eg, CFTR deltaF508). Attention to genomic regions of
diagnostic importance that are particularly difficult to
sequence and/or analyze is warranted. Examples include
functional genes that have highly homologous correlates in
the genome (eg, pseudogenes and paralogs). The validation
must assess both sequencing chemistry and bioinformatics
because of their interdependency. Assessment of the assay’s
ability to identify causal variants in the application of
undiagnosed disorders requires unique approaches. Beyond
the technical component of variant calling, it is necessary to
validate the overall informatics pipeline, which includes
variant filtration, prioritization, and correlation with phenotype. This typically involves inclusion of samples with
pathogenic variants from previously characterized patients
with autosomal recessive, dominant, and de novo genetic
disorders.
QUALITY ASSURANCE AND QUALITY CONTROL
Laboratories are expected to develop their quality
assurance and quality control programs according to the
guidelines issued by Clinical Laboratory Improvement
Amendments/College of American Pathologists regulatory
bodies. Additional certifications such as those from New
York State, the Joint Commission, and the International
Organization for Standardization may need additional
Whole-Exome and Whole-Genome Sequencing—Hegde et al 803

Figure 3. Example: trio sequencing for identification of a de novo change in the ASXL3 gene. A, Identification of c.3349C. T (p.R1117X) variant in
ASXL3 gene by whole-exome sequencing. B, Pedigree and confirmation of variant using Sanger sequencing.

considerations for quality assurance/quality control in the
laboratory.
PROFICIENCY TESTING AND REFERENCE MATERIALS
It is recommended that laboratories participate in
proficiency testing programs for WES and WGS. These
programs are available through a few organizations.
Proficiency testing offered through the College of American
Pathologists for WES and WGS is a method-based
proficiency testing survey based on a highly characterized
human genomic DNA sample. Launched as an educational
survey in 2015 and converted to a graded survey in 2016, the
College of American Pathologists NGS methods-based
survey is sent to participating laboratories twice per year.
This survey also functions to assess laboratories performing
a variety of germline gene panel assays. Laboratories
performing WES and WGS are required to sequence the
provided genomic DNA and report their results on 50
chromosomal positions or intervals that contain singlenucleotide variants, insertions, or deletions or are reference
wild type. Laboratories are required to indicate type of
variant if present and zygosity, and to describe variants
using Human Genome Variation Society nomenclature.
804 Arch Pathol Lab Med—Vol 141, June 2017

A second proficiency testing program for WES was
launched as a pilot in 2012 through the European Molecular
Genetics Quality Network. European proficiency testing/
external quality assessment challenges are provided by both
national and international organizations, with additional
participation by laboratories from outside Europe. At this
time the European Molecular Genetics Quality Network
continues to describe their program as a pilot for assessment
of germline variants. Participating laboratories receive a
single genomic DNA sample per survey that can be used to
assess their ability to identify germline variants during
exome sequencing as well as single-gene and gene-panel
testing.
In addition to proficiency testing programs, laboratories
performing exome and genome sequencing have greatly
benefited from the growing availability of genomic reference
materials. Notably, the Genome in a Bottle program
through the National Institute of Standards and Technology
has developed reference materials, reference methods, and
reference data needed to assess confidence in human
whole-genome variant calls. The well-characterized and
stable reference materials are provided with metrics for
validation, quality control, and quality assurance. A full
description of sources and types of bias/error is also
Whole-Exome and Whole-Genome Sequencing—Hegde et al

provided with each material. Currently the Genome in a
Bottle Consortium program provides 7 validated reference
materials. Because of their being initially available, the most
prominent reference materials are the GM12878 and
GM24385 cell lines (deposited in the Coriell Cell Repository). These have been widely used by laboratories during
optimization of their WES and WGS assays.
We thank Patricia Vasalos, BS, and Jaimie Halley, BS, for
providing support and coordination for all the next-generation
sequencing validation manuscripts in this series; they both are
employees of the College of American Pathologists (Northfield,
Illinois).
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